• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Developments in Oncolytic Viruses - An Emerging Approach to Cancer Therapeutics Product Image

Developments in Oncolytic Viruses - An Emerging Approach to Cancer Therapeutics

  • ID: 235054
  • December 2004
  • 35 pages
  • Lead Discovery

Oncolytic virus therapy is successful in providing an alternative treatment for cancer. Viruses have now been engineered to selectively replicate and kill cancer cells. Over the past few years, new insights into the molecular mechanisms of viral cytotoxicity have provided the scientific rationale to design more effective oncolytic viruses. Research activity is bearing fruit and a number of viruses are now in phase I/II development.

This report introduces the emerging field of oncolytic viruses and the various benefits that oncolytic virology can offer in the treatment of cancer. Clinical data suggest that oncolytic viruses may offer therapeutic advantages over existing cancer therapies such as chemotherapy and radiation and may even act synergistically with these conventional approaches. This report evaluates preclinical and clinical data on oncolytic viruses that have entered the clinic.

The resistance of cancers to conventional therapies has inspired the search for novel strategies and more in depth studies on cytolytic viruses. The selection of the optimal treatment for a cancer patient depends upon the type and location of the tumor and this is also likely to be the READ MORE >

1. Introduction

Oncolytic Viruses
Approaches in the Development of Engineered Oncolytic Viruses
Main Groups of Viral Vectors
2. G207 Viral Vector: Treatment of High Grade Astrocytomas

Advantages and Efficacy of the G207 Viral Vector
Safety of the Viral G207 Vector
3. Adenovirus-Mediated Gene Therapy

Transductionally Targeted Adenoviruses
Transcriptionally Targeted Adenoviruses
Double-Targeted Adenoviruses
Conditionally Replicating Adenoviruses (CRAds)
4. Cytolytic Viruses

Naturally Occurring Oncotropic Viruses
Selection of the Optimal Treatment
5. Herpesvirus

6. Reovirus

6. INGN 007 (VRX-007) and INGN 009 (VRX-009): Treatment of Lung and Colon Tumours

7. Recombinant Vesicular Stomatitis Virus (RVSV)

8. Conclusion

9. Companies leading the development of oncolytic viruses and product profiles

Cell Genesys
Crusade Laboratories
10. Case Study: Pulmonary Malignant Granular Cell Tumor

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos